X4 Pharmaceuticals shares surge 16.92% intraday after Stifel upgrades rating to Buy and raises price target to $10.

viernes, 5 de diciembre de 2025, 9:39 am ET1 min de lectura
XFOR--
X4 Pharmaceuticals surged 16.92% intraday after Stifel initiated coverage with a "Buy" rating and raised its price target to $10.00 from $7.50, signaling strong analyst confidence. The move followed the company’s successful .

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios